Cancer has essentially hijacked the immune system's own peacekeeping force
Among the many ways cancer extends its reach, its colonization of bone has long carried a particular mystery: why does the body's own immune system stand aside and allow it? Researchers at Baylor College of Medicine have now mapped the answer with unusual precision, revealing that cancer cells chemically instruct bone's resident immune guardians to abandon their post and shield the tumor instead. The discovery points toward an existing class of drugs — already approved for breast cancer — as a potential key to unlocking immune defenses across multiple cancer types and in patients of all genders.
- Cancer's ability to reprogram the immune system's own cells into tumor protectors has been exposed at the molecular level for the first time in bone tissue.
- A newly developed tagging technique called SAMENT revealed that bone metastases are uniquely surrounded by estrogen-receptor-activated macrophages that physically and chemically block T cells from reaching tumors.
- The mechanism traces to cancer cells shipping fatty acids via microscopic vesicles to nearby macrophages, triggering a metabolic switch that transforms defenders into bodyguards.
- Genetically removing estrogen receptor alpha from macrophages in mice slowed tumor growth and reduced metastatic spread without harming normal bone structure — a critical proof of concept.
- FDA-approved estrogen-blocking drug fulvestrant restored T cell infiltration into bone tumors in preclinical models, opening a credible path toward human clinical trials combining this approach with immunotherapy.
Cancer's most dangerous maneuver is not the original tumor — it is the ability to send colonies into distant organs. Bone is among the most common destinations, and for years scientists suspected the bone environment was somehow complicit in welcoming metastatic cells. What remained unclear was which cells were doing the welcoming, and how cancer persuaded them to switch allegiances.
A team at Baylor College of Medicine developed a technique called SAMENT to answer exactly that. By selectively marking normal cells that come into direct physical contact with cancer cells during metastasis, the method revealed the cellular neighborhoods cancer actually inhabits. Across multiple organs, those neighborhoods were dominated by macrophages and nearly empty of T cells. But bone stood apart: there, the macrophages surrounding tumors had activated a protein called estrogen receptor alpha, or ERα — a molecule famous in breast cancer biology but almost unstudied in immune cells. When the researchers examined human bone metastasis samples from patients with breast, lung, and kidney cancers — including men — the same ERα-active macrophages appeared. This was not a disease-specific quirk. It was a fundamental mechanism.
Tracing the process backward, the team found that cancer cells package fatty acids into tiny extracellular vesicles and deliver them to nearby macrophages. The absorbed fatty acids trigger a metabolic cascade that switches on ERα, transforming the macrophages from immune defenders into a physical and chemical barrier that locks T cells out of the tumor entirely. The cancer had hijacked the immune system's own peacekeeping force.
To confirm the mechanism, the researchers bred mice lacking ERα specifically in macrophages. Tumors colonized bone more slowly, metastatic spread was reduced, and — critically — the mice's bones remained structurally healthy. The target appeared clean. When the team then treated bone metastasis models with fulvestrant, an FDA-approved estrogen receptor degrader, T cells broke through the barrier and began killing tumor cells. The immune system, once excluded, could finally act.
The researchers now call for clinical trials testing estrogen-blocking therapies in bone metastasis patients across cancer types, potentially combined with checkpoint immunotherapies — though early combination experiments showed no synergy yet. The mechanism is established, the preclinical evidence is strong, and the drug already exists. The remaining work is proving it holds in people.
Cancer's deadliest trick is not the tumor itself—it's the ability to escape the original site and establish new colonies in distant organs. Bone is one of the most common destinations, and for years researchers have known that something about the bone microenvironment makes it hospitable to metastatic growth. What they didn't know was exactly which cells were doing the welcoming, or how cancer cells convinced them to switch sides.
Scientists at Baylor College of Medicine have now developed a technique that answers both questions. The method, called SAMENT (sortase A-based microenvironment niche tagging), works by selectively marking normal cells that come into direct physical contact with cancer cells as tumors spread through the body. It's a way of asking: which cells is the cancer actually touching, and what are they doing there? When Xiang Zhang's team applied SAMENT to study metastasis across multiple organs—bone, lung, liver, and brain—they found a pattern. In all these sites, the cellular neighborhoods surrounding cancer cells looked remarkably similar: lots of macrophages, a type of immune cell that normally fights infection and cancer, and very few T cells, the immune soldiers that typically kill tumor cells. But bone metastases were different. Something unusual was happening there.
In bone specifically, the macrophages surrounding cancer cells had activated a protein called estrogen receptor alpha, or ERα. This protein is famous in breast cancer research, where it drives hormone-responsive tumors, but almost nobody had studied it in immune cells before. The finding was striking enough that the team checked human bone metastasis samples from patients with breast, lung, and kidney cancers—including men. The ERα-active macrophages were there too, across cancer types and across genders. This was not a quirk of one disease or one population. It was a fundamental mechanism of how cancer colonizes bone.
The researchers then traced the mechanism backward. How were cancer cells convincing macrophages to activate ERα in the first place? The answer involved tiny particles called extracellular vesicles—essentially molecular delivery trucks. Cancer cells package fatty acids into these vesicles and send them to nearby macrophages. Once the macrophages absorb the fatty acids, a metabolic cascade begins that switches on ERα signaling. And once ERα is active, the macrophages transform. They stop acting as immune defenders and start acting as bodyguards for the cancer. They form a physical and chemical barrier that prevents T cells from ever reaching the tumor cells. The cancer has essentially hijacked the immune system's own peacekeeping force and turned it into a wall.
To prove this mechanism actually drives bone metastasis, the team performed a genetic experiment. They bred mice in which the ERα gene had been removed specifically from macrophages—leaving ERα intact everywhere else in the body. The results were striking. Cancer cells struggled to colonize bone. Tumors grew more slowly. Metastases that typically spread from bone to other organs were reduced. And critically, removing ERα from macrophages did not damage normal bone health. The mice's bones remained structurally sound, still remodeling and functioning normally. This suggested that blocking ERα in macrophages could be a therapeutic target without the collateral damage of disrupting bone itself.
The team then tested whether existing drugs could achieve the same effect. They used fulvestrant, an FDA-approved estrogen receptor degrader already used to treat breast cancer. When mice with bone metastases were treated with fulvestrant, something remarkable happened: T cells were able to infiltrate the metastatic lesions and kill tumor cells. The barrier had been breached. The immune system, once locked out, could finally do its job. Zhang and his colleagues now argue that these findings warrant human clinical trials testing estrogen-blocking therapies in patients with bone metastases across multiple cancer types. They suggest combining these drugs with immunotherapies—the checkpoint inhibitors that have transformed cancer treatment in recent years—though their initial experiments with one such combination did not show synergy. The mechanism is clear, the preclinical evidence is solid, and the drug already exists. What remains is the harder work of proving it works in people.
Notable Quotes
Our lab is interested in better understanding what cellular and molecular features support metastasis as these could guide the development of therapies to prevent, slow down, or eliminate them.— Xiang Zhang, Baylor College of Medicine
When macrophage ERα was genetically removed or when mice were treated with fulvestrant, T cells were able to enter metastatic lesions in bone and kill tumor cells.— Xiang Zhang
The Hearth Conversation Another angle on the story
Why does bone metastasis seem to be special? The cancer cells are spreading to multiple organs, but something different happens in bone.
The bone microenvironment has unique cellular properties. It's rich in macrophages, and bone has its own specialized cell types—osteoblasts and osteoclasts—that remodel the skeleton. Cancer cells seem to exploit this specific ecosystem in a way they don't in lung or liver.
So the cancer cells are actively communicating with the macrophages? They're not just hiding there?
Exactly. They're sending molecular signals—fatty acids packaged in tiny vesicles—that reprogram the macrophages' metabolism. It's a deliberate hijacking, not passive coexistence.
And the estrogen receptor is the key to that reprogramming?
In bone, yes. The fatty acids activate a metabolic pathway that turns on ERα signaling in macrophages. Once that happens, the macrophages become immunosuppressive. They physically block T cells from reaching the tumor.
But estrogen receptor blockers already exist. Why hasn't this been tried before?
Because nobody knew ERα was active in bone macrophages during metastasis. It's not something you'd think to look for. The SAMENT technique made it visible for the first time.
What happens if you remove ERα from macrophages in mice?
Cancer cells can barely colonize bone. Tumors grow slowly. And the mice's bones stay healthy—normal structure, normal remodeling. That's the crucial part. You're not breaking bone to fight cancer.
So the next step is human trials?
Yes, but probably in combination with other therapies. The estrogen blocker alone might not be enough. The real power might come from combining it with immunotherapies that help T cells attack cancer from a different angle.